Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Table 2 Patient characteristics: table below summarizes the individual patient characteristics

Patient	Age at start of P (y)	Stage at diagn-osis	Prior treatment before KI	PD-L1 status	KI	Time on KI alone (m)	Time on KI + P (m)	Change in target lesions and BOR on KI + P	PFS On KI + P (m)	OS from KI (m)	OS from KI+P (m)	Alive (A)/Deceased (D)
1	56	IVC	BC, CXRT	5%	DT	4.3	3.1	32% PD	0.7	7.4	3.1	D
2	68	IVC	BC	30%	DT	9.6	3.8	21% PD	1.5	13.4	3.8	D
3	57	IVB	Sg, CXRT	80%	L	1.9	6.9	19% PD	1.5	8.9	6.9	D
4	58	IVC	Sg, CXRT	5%	DT	26.2	13.9	−7% SD	0.6	40.1	13.9	A
5	60	IVC	BC	50%	L	5.5	15.8	−8% SD	12.8	21.4	15.8	A
6	47	IVB	Sg, CXRT	60%	DT	2.4	3	−14% SD	3	5.4	3	D
7	69	IVC	CXRT	n/A	DT	2	4.1	−19% SD	3.1	6.2	4.1	D
8	60	IVC	SC, BC	> 95%	DT	1.2	6.2	−35% PR	6.2	7.4	6.2	A
9	84	IVC	Sg-Lobectomy	> 10%	L	2.1	8.3	−45% PR	8.3	10.4	8.3	D
10	57	IVC	SC, XRT	n/A	L	2.4	16.1	−47% PR	13.1	18.5	16.1	A
11	73	IVC	Sg, RAI	20%	T	3.7	4.9	−48% PR	2.6	6.7	4.9	A
12	76	IVB	Sg, RAI	> 90%	L	1.5	5	−69% PR	5	5.8	5	D

Sg Surgery, CXRT Chemoradiation, BC Bridging chemotherapy with paclitaxel with or without carboplatin while awaiting KI, SC Systemic cytotoxic chemotherapy, XRT external beam radiation, RAI radioactive iodine, DT dabrafenib+trametinib, L lenvatinib, T trametinib alone, w weeks, m months, y years, KI kinase inhibitor, BOR best overall response, PFS progression-free survival, OS overall survival, PD progressive disease, SD stable disease, PR, partial response